| Real World Study on the Use of Cemiplimab in Adult Patients in UK (NCT05493826) | Sanofi | 2022-07-18 |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (NCT05286294) | Oslo University Hospital | 2022-06-28 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (NCT05256381) | SOTIO Biotech AG | 2022-06-21 |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy (NCT05358938) | H. Lee Moffitt Cancer Center and Research Institute | 2022-06-21 |
| The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) (NCT05238363) | Shanghai Henlius Biotech | 2022-06-15 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC (NCT05220748) | Rakuten Medical, Inc. | 2022-03-24 |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region (NCT05482880) | Maastricht University Medical Center | 2022-02-28 |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (NCT04985825) | Pega-One S.A.S. | 2021-12-16 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (NCT04916002) | Regeneron Pharmaceuticals | 2021-11-30 |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC (NCT06046625) | Maastricht University Medical Center | 2021-11-01 |
| Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck (NCT05108090) | Indiana University | 2021-10-25 |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (NCT04975152) | H. Lee Moffitt Cancer Center and Research Institute | 2021-10-22 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma (NCT04710498) | Stanford University | 2021-06-22 |
| Personalised Immunotherapy Platform (NCT06536257) | Melanoma Institute Australia | 2021-06-08 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma (NCT04632433) | Fondazione Melanoma Onlus | 2021-02-10 |
| Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck (NCT04664582) | Jewish General Hospital | 2020-11-26 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (NCT04502888) | Shattuck Labs, Inc. | 2020-09-17 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (NCT04620200) | The Netherlands Cancer Institute | 2020-08-11 |
| Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC (NCT04242173) | H. Lee Moffitt Cancer Center and Research Institute | 2020-06-25 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542) | Bicara Therapeutics | 2020-06-01 |
| Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma (NCT04154943) | Regeneron Pharmaceuticals | 2020-03-10 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (NCT04160065) | TuHURA Biosciences, Inc. | 2020-03-03 |
| Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (NCT04389112) | University Hospital, Bordeaux | 2020-02-28 |
| Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study (NCT04252612) | H. Lee Moffitt Cancer Center and Research Institute | 2020-01-30 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 (NCT03901573) | NeoImmuneTech | 2019-12-26 |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (NCT04050436) | Replimune, Inc. | 2019-10-08 |
| A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors (NCT03982212) | University of Kansas Medical Center | 2019-07-26 |
| CemiplimAb Survivorship Epidemiology (NCT03836105) | Regeneron Pharmaceuticals | 2019-06-27 |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (NCT03969004) | Regeneron Pharmaceuticals | 2019-06-04 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (NCT03889912) | Regeneron Pharmaceuticals | 2019-04-11 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (NCT03524326) | Memorial Sloan Kettering Cancer Center | 2018-04-30 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03082534) | University of California, San Diego | 2017-03-28 |
| New Strategies Against Cutaneous Squamous Cell Carcinoma (NCT02672254) | Corporacion Parc Tauli | 2016-01-01 |
| Treatment With Nab-paclitaxel in Cutaneous SCC (NCT02076243) | Icahn School of Medicine at Mount Sinai | 2014-03-01 |
| IFx-Hu2.0 Expanded Access Program (NCT04853602) | TuHURA Biosciences, Inc. | |
| Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (NCT03492489) | Regeneron Pharmaceuticals | |